Corey Pelletier
Overview
Explore the profile of Corey Pelletier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malfertheiner P, Moss S, Daniele P, Pelletier C, Jacob R, Tremblay G, et al.
Gastro Hep Adv
. 2024 Aug;
1(5):824-834.
PMID: 39131848
Background And Aims: Effective acid suppression is a crucial component of () eradication regimens. Approved treatments include dual, triple, and quadruple therapies composed of certain antibiotics in combination with proton...
2.
Howden C, Spechler S, Vaezi M, Fendrick A, Atkinson C, Pelletier C, et al.
Gastro Hep Adv
. 2024 Aug;
1(2):231-240.
PMID: 39131129
Background And Aims: eradication rates have declined as antibiotic resistance rates have increased. In addition, adherence to treatment guidelines is suboptimal. It is therefore important that contemporary, real-world evidence of...
3.
Yadlapati R, Cappell K, Sedgley R, Pelletier C, Jacob R, Bonafede M, et al.
Adv Ther
. 2023 Oct;
40(12):5489-5501.
PMID: 37837526
Introduction: Erosive esophagitis (EE) is a severe form of gastroesophageal reflux disease commonly treated with proton pump inhibitors (PPIs). The aim of this retrospective, observational cohort study was to describe...
4.
Shah S, Cappell K, Sedgley R, Pelletier C, Jacob R, Bonafede M, et al.
J Med Econ
. 2023 Sep;
26(1):1227-1236.
PMID: 37748019
Aims: The study objectives were to 1) characterize the cost drivers of patients with (HP) and 2) estimate HP-related cost savings following lab-confirmed HP eradication with US guideline-recommended treatment compared...
5.
Hudgens S, Howerter A, Keith S, Evans C, Pelletier C
Health Qual Life Outcomes
. 2023 Aug;
21(1):83.
PMID: 37553594
Background: Psoriasis is a common autoimmune dermatologic condition which has a pronounced negative impact on patient quality of life and disease burden. Currently, there are a number of treatments available...
6.
Moss S, Chey W, Daniele P, Pelletier C, Jacob R, Tremblay G, et al.
Therap Adv Gastroenterol
. 2023 Jun;
16:17562848231167284.
PMID: 37388121
Background: eradication rates achieved with clarithromycin-based triple therapies are declining due to antibiotic resistance, but data regarding temporal changes in efficacy with these eradication therapies are scarce. Objective: To evaluate...
7.
Howden C, Cook E, Swallow E, Yang K, Guo H, Pelletier C, et al.
Therap Adv Gastroenterol
. 2023 May;
16:17562848231168714.
PMID: 37153499
Background: Japanese guidelines recommend triple therapy with vonoprazan or a proton pump inhibitor (PPI) in combination with antibiotics to treat () infection. While studies have shown improved eradication rates and...
8.
Shah S, Cappell K, Sedgley R, Pelletier C, Jacob R, Bonafede M, et al.
Sci Rep
. 2023 Jan;
13(1):1375.
PMID: 36697470
Approximately 36% of the United States (US) population is infected with Helicobacter pylori (HP), a known major risk factor for peptic ulcer disease and gastric cancer. HP eradication reduces the...
9.
Yadlapati R, Hubscher E, Pelletier C, Jacob R, Brackley A, Shah S
Expert Rev Gastroenterol Hepatol
. 2022 Oct;
16(10):967-980.
PMID: 36254610
Introduction: Erosive esophagitis (EE) occurs when refluxate from the stomach causes T-lymphocyte infiltration of the esophageal mucosa, resulting in mucosal breaks. Currently, therapy with proton-pump inhibitors (PPIs) is the standard...
10.
Vaezi M, Brunton S, Fendrick A, Howden C, Atkinson C, Pelletier C, et al.
BMJ Open Gastroenterol
. 2022 Jul;
9(1).
PMID: 35868653
Objective: Management of erosive oesophagitis (EE) remains suboptimal, with many patients experiencing incomplete healing, ongoing symptoms, and relapse despite proton pump inhibitor (PPI) treatment. The Study of Acid-Related Disorders investigated...